A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease

[...]once-daily doses of the MABA AZD8871 in patients with COPD delivered significant bronchodilation and clinically meaningful improvement of symptoms. Author Contributions: D.S. is the overall guarantor of this report and takes responsibility for the content, including the data and analysis; L.J., U.W.H., A.J., M.-P.M., V.B., A.L., A.A., C.A., and I.P. contributed to the study design, concept, and/or interpretation; D.S. and R.F. contributed to data acquisition; A.J. and M.-P.M. performed the statistical analyses; and all authors critically revised the manuscript and approved the submitted version. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et at Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary.